Qiagen N.V. (QGEN) Stock Price & Analysis
Qiagen N.V. (QGEN) closed at USD 46.17 on Thursday, October 15, 2026, up 1.34% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 45.56; the Oct 15, 2026 session ranged USD 45.6–46.49 on volume of 1,312,641 shares. Market capitalization is $9.53B, with a 52-week range of USD 32.53–57.82 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/QGEN.md
Key facts (QGEN)
- Analysts: Buy (mean 2.13 on a 1–5 scale) (16 analysts), mean target USD 48.13 (range 40–55).
- Total return with dividends: 1Y -3.2% vs S&P 500 +18.1%; 5Y -9.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.62, revenue estimate $534M.
Analysts (QGEN)
Consensus Buy (mean 2.13 on a 1–5 scale), 16 analysts; mean target USD 48.13 (low 40, high 55).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | JP Morgan | Target raised | Overweight | $50 → $55 |
| 2026-10-06 | Barclays | Upgrade | Equal-Weight → Overweight | $40 → $55 |
| 2026-09-09 | UBS | Target lowered | Neutral | $52 → $47 |
| 2026-08-10 | Citigroup | Target raised | Neutral | $38 → $45 |
| 2026-08-07 | Barclays | Target raised | Equal-Weight | $38 → $40 |
| 2026-08-07 | JP Morgan | Target raised | Overweight | $45 → $50 |
| 2026-06-23 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $40 → $42 |
Total return (dividends reinvested) (QGEN)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -3.2% | -9.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -3.2% | -1.9% |
| Volatility (annualized) | 35.1% | 26.1% |
| Max drawdown | -41.4% (Jan 2026→May 2026) | -41.4% (Nov 2021→May 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 46.17 |
|---|---|
| Change | ▲ 1.34% (up) |
| Previous Close | USD 45.56 |
| Open | USD 45.96 |
| Day Range | USD 45.6 – 46.49 |
| 52-Week Range | USD 32.53 – 57.82 |
| Volume | 1,312,641 shares |
| Market Cap | $9.53B |
| Exchange | NYQ |
Technical Analysis (QGEN)
Nexqual's technical model rates QGEN "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.98 (neutral) |
| vs SMA50 | Above (USD 43.72) |
| MACD | 0.65 (positive) |
Analyst Ratings (QGEN)
Wall Street analysts rate QGEN "Buy" based on 16 analysts, with a mean price target of USD 48.13 (range USD 40–55), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 48.13 |
| High Target | USD 55 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 9 / 7 / 0 |
Earnings (QGEN)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.62 |
| Revenue Estimate | $533.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.62 vs est 0.6 ▲ beat |
| 2026-03-31 | USD 0.54 vs est 0.54 ▲ beat |
| 2025-12-31 | USD 0.62 vs est 0.62 ▲ beat |
| 2025-09-30 | USD 0.64 vs est 0.62 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (QGEN)
| Total Revenue | $2.10B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.30% |
| Gross Margin | +66.39% |
| Operating Margin | +26.32% |
| Profit Margin | +19.49% |
| ROE | +11.93% |
| Debt / Equity | 0.49 |
| Current Ratio | 2.85 |
| Total Cash | $793.50M |
| Total Debt | $1.65B |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (QGEN)
Nexqual rates Qiagen N.V.'s overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 26% |
| Balance Sheet | Strong — $794M cash vs $1.65B debt |
| Cash Flow | Solid — Operating cash flow $654M (TTM) |
| Efficiency | Mixed — ROE 12%, ROA 5.9% |
Ownership (QGEN)
| Insider Ownership | +0.48% |
|---|---|
| Institutional Ownership | +79.29% |
| Shares Outstanding | 206.50M |
| Float | 205.17M |
| Short % of Float | +4.21% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (QGEN)
Qiagen N.V. is led by Jonathan M. Pratt (age 55), CEO & Member of Management Board, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Member of Management Board | Jonathan M. Pratt (age 55) |
|---|---|
| CFO, MD & Member of Management Board | Roland Sackers (age 57) |
| Senior Vice President of Life Science Business Area | Thomas Schweins |
| Senior Director & Head of External Communications | Thomas Theuringer |
Major Backers & Investors (QGEN)
Notable institutional backers of Qiagen N.V. include Wellington Management, Price (T.Rowe) Associates Inc, MFS Series Trust XVII-MFS International Equity Fund, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.02% |
| Price (T.Rowe) Associates Inc | 5.51% |
| MFS Series Trust XVII-MFS International Equity Fund | 3.4% |
| Principal Financial Group, Inc. | 3.23% |
| Goldman Sachs | 2.86% |
| TR PRICE-Price (T.Rowe) International Growth Equity Trust | 2.61% |
| Morgan Stanley | 2.45% |
| Earnest Partners LLC | 2.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.38% |
| BlackRock | 3.61% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICLR | ICON plc | USD 175.13 | ▲ 6.57% |
| CRL | Charles River Laboratories Inte | USD 306.24 | ▲ 2.41% |
| GRAL | GRAIL, Inc. | USD 135.46 | ▼ 3.48% |
| RDNT | RadNet, Inc. | USD 70.41 | ▼ 1.54% |
| RVTY | Revvity, Inc. | USD 154.71 | ▼ 0.24% |
| MEDP | Medpace Holdings, Inc. | USD 628.6 | ▲ 3.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt